EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction

Yinuo Yang iD, Mengyao Mu, Ke Ren, Hui Liu, Pengju Ma, Yingqi Wang, Mengmeng Zhang, Xueli Xu, Wenzhe Li iD, Wenshuang Gao iD, Xiao Sun iD, Qiang Zhu iD

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.71657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Yinuo Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, Shandong, China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver Cirrhosis, Transforming Growth Factor beta, Ferroptosis. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shandong Provincial Key Research and Development Program (International Science and Technology Cooperation), Natural Science Foundation of Shandong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis and its terminal stage, cirrhosis, represent a major cause of morbidity and mortality related to hepatic pathologies. Activated hepatic stellate cells (aHSCs) are the principal drivers of fibrogenesis and therefore constitute key therapeutic targets. Lanifibranor, a pan‐peroxisome proliferator‐activated receptor agonist, has shown promising antifibrotic efficacy; however, its clinical application is limited by rapid systemic clearance and insufficient accumulation in fibrotic liver tissue. In this study, we report an aHSC‐targeted nanoplatform for lanifibranor delivery based on vitamin A‐functionalized two‐dimensional iron sulfide nanosheets (FeS‐V A @lanifibranor, FVL). Lanifibranor was electrostatically loaded onto vitamin A‐modified FeS nanosheets, enabling selective uptake by aHSCs and enhancing hepatic accumulation of lanifibranor. FVL significantly downregulated the expression of key fibrogenic markers and markedly reduced collagen accumulation. Mechanistically, the therapeutic efficacy of FVL arises from a dual‐action mechanism: inhibition of SMAD2/3 phosphorylation within the transforming growth factor‐β (TGF‐β) signaling pathway and induction of ferroptosis in aHSCs. In conclusion, this study provides an effective aHSC‐specific nanotherapeutic strategy for liver fibrosis treatment and highlights the translational potential of FVL nanoplatforms for targeted antifibrotic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsLiver CirrhosisTransforming Growth Factor betaFerroptosisAnimalsHumansSignal TransductionSmad2 ProteinMiceMaleSmad3 Protein

Stichwörter der Autor:innen

TGF‐β signaling axisferroptosishepatic stellate cellslanifibranorliver fibrosis

Substanzen

Transforming Growth Factor betaSmad2 ProteinSmad3 Protein

Autor:innen und Institutionen

  • Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, Shandong, China.
  • Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji'nan, Shandong, China.
  • Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Ji'nan, Shandong, China.
  • School of Science, Shandong Jianzhu University, Ji'nan, Shandong, China.
  • Central Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji'nan, Shandong, China.
  • Rehabilitation Center, Qilu Hospital of Shandong University, Ji'nan, Shandong, China.

ORCID-Profile: Yinuo Yang, Wenzhe Li, Wenshuang Gao, Xiao Sun, Qiang Zhu

Förderung

  • National Natural Science Foundation of China
  • Shandong Provincial Key Research and Development Program (International Science and Technology Cooperation)
  • Natural Science Foundation of Shandong
  • Scientific Research Cultivation Foundation of Shandong Provincial Hospital
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Yang, Y., Mu, M., Ren, K., Liu, H., Ma, P., Wang, Y., Zhang, M., Xu, X., Li, W., Gao, W., Sun, X., & Zhu, Q. (2026). Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71657

Vancouver

Yang Y, Mu M, Ren K, Liu H, Ma P, Wang Y, et al. Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71657

BibTeX
@article{Yang2026,
  author = {Yang, Yinuo and Mu, Mengyao and Ren, Ke and Liu, Hui and Ma, Pengju and Wang, Yingqi and Zhang, Mengmeng and Xu, Xueli and Li, Wenzhe and Gao, Wenshuang and Sun, Xiao and Zhu, Qiang},
  title = {Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.71657}
}
Kostenlos starten →